This page is educational and non-prescriptive. It describes the clinical evidence and approved labeling for afamelanotide and does not recommend any use of it.
An approved drug, for one rare disease
Melanotan I deserves a clear statement that applies to almost nothing else on this site: it is an approved medicine. Under the name afamelanotide, sold as Scenesse, it completed randomized controlled trials, cleared regulatory review, and carries an FDA-approved label.
The indication is narrow and specific: to increase pain-free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP), a rare inherited photodermatosis in which sunlight causes severe pain (Scenesse labeling, DailyMed). It is not approved for tanning, cosmetic pigmentation, photoprotection in the general population, or anything else. The gap between "approved drug" and "approved for the reason people buy it" is the entire subject of this page.
The two pivotal trials
The evidence supporting approval was published in The New England Journal of Medicine in 2015 (PMID 26132941). Two multicenter, randomized, double-blind, placebo-controlled trials tested subcutaneous implants containing 16 mg of afamelanotide, administered every 60 days.
- European Union trial: 74 patients, five implants, 180-day study period.
- United States trial: 94 patients, three implants, 270-day study period.
- Primary endpoint: hours of direct sunlight exposure without pain.
In the US trial, median pain-free time after six months was 69.4 hours on afamelanotide versus 40.8 hours on placebo (p=0.04). In the EU trial, median pain-free time after nine months was 6.0 hours versus 0.8 hours (p=0.005), and phototoxic reactions numbered 77 versus 146 (p=0.04). Quality of life improved with treatment in both trials, measured by validated questionnaires. Adverse events were mostly mild, and serious adverse events were not attributed to the drug.
Two features of these results reward attention. The absolute numbers differ enormously between the two trials—69.4 hours versus 6.0 hours as the treated median—which reflects different study durations, seasons, and patient populations rather than an inconsistent drug effect. And the endpoint is striking in its own right: for the EU cohort, the untreated median was 48 minutes of sunlight per study period. That is the baseline this drug was measured against, and it explains why a rare-disease approval was warranted.
What the approved label says
The Scenesse label sets out the practical constraints of the approved product:
- A 16 mg implant placed subcutaneously every 2 months—a physician-administered implant, not a self-injected vial.
- Hypersensitivity reactions, including anaphylaxis, have been reported; the label directs removal of the implant if they occur and no further treatment.
- Skin monitoring: because the drug darkens existing moles and freckles by design, full-body skin examinations are recommended twice yearly to track new or changing lesions.
- Sun protection continues. Patients are directed to maintain light-protection measures during treatment—the drug increases tolerable exposure, it does not remove the underlying disease.
That mole-monitoring requirement on an approved melanocortin agonist is the most transferable finding on this page, since darkening of pigmented lesions is a mechanistic consequence of the drug class rather than a quirk of one product.
Why none of this covers cosmetic use
Afamelanotide is an α-MSH analogue that activates melanocortin receptors and stimulates eumelanin synthesis; the same pharmacology that helps EPP patients is what produces tanning. But the trial evidence above cannot be transferred to unregulated Melanotan I for several concrete reasons:
- Different product. The trials used a manufactured controlled-release implant with a known dose. Research-chemical vials are lyophilized powder of unverified identity, purity, and quantity.
- Different population. Participants had a rare genetic disease with a specific unmet need. Benefit-risk in that setting does not describe benefit-risk in a healthy adult seeking a tan.
- Different endpoint. The trials measured pain-free sunlight hours, not cosmetic pigmentation, and not any safety outcome over years.
- Different oversight. Approved use involves a clinician-placed implant, twice-yearly dermatological surveillance, and adverse-event reporting.
"FDA-approved" is accurate about afamelanotide and misleading about Melanotan I as sold. Both statements can be true because they are about different things.